Abstracts tagged "remission"

Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…
Abstract Number: 169 • 2015 ACR/ARHP Annual Meeting
Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target
Myrthe van der Ven¹, David F. Ten Cate², Andreas Gerards³, Johannes Jacobs⁴, Nanno Swen⁵, M.H. de Jager⁶, Natalja Basoski⁷, Cees Haagsma⁸, Mieke Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medical Center Alkmaar, Alkmaar, Netherlands, ⁶Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁷Rheumatology, Maasstadziekenhuis, Rotterdam, Netherlands, ⁸Rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands
Background/Purpose: The feet are often involved in rheumatoid arthritis (RA), but physical examination of the metatarsophalangeal (MTP) joints to detect arthritis is challenging especially in…
Abstract Number: 2132 • 2014 ACR/ARHP Annual Meeting
What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity?
Violaine Foltz¹, Lisa Biale², Frederique Gandjbakhch¹, Laure Gossec¹, Pierre Bourgeois¹, Benjamin Granger³ and Bruno Fautrel¹, ¹Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France, ²Rheumatology, Instruction des Armées Begin hospital, Saint-mande, France, ³Departement de santé publique, information medicale et biostatistiques, unite biotstatistiques, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose Persistent inflammation on Power Doppler (PD) by ultrasound (US) was associated with relapse and structural progression after one year of follow up in a…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Paul Studenic¹, Josef Smolen² and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA
Abstract Number: 940 • 2014 ACR/ARHP Annual Meeting
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Judith Haschka^1,2, Jürgen Rech³, Matthias Englbrecht¹, Stephanie Finzel¹, Michaela Reiser¹, Axel J. Hueber¹, Arnd Kleyer¹, Hans-Peter Tony⁴, Martin Fleck⁵, Karin Manger⁶, Wolfgang Ochs⁷, Jörg Wendler⁸, Hanns-Martin Lorenz⁹, Hubert Nüßlein¹⁰, Rieke Alten¹¹, Winfried Demary¹² and Georg Schett¹, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 2, The VINFORCE Study Group, St. Vincent Hospital Vienna, Vienna, Austria, ³Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 2, University Hospital Würzburg, Würzburg, Germany, ⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ⁶Rheumatology Practice Bamberg, Bamberg, Germany, ⁷Rheumatology Practice Bayreuth, Bayreuth, Germany, ⁸Rheumatology Practice Erlangen, Erlangen, Germany, ⁹Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ¹⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ¹¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹²Rheumatolgy Practice Hildesheim, Hildesheim, Germany
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…
Abstract Number: 908 • 2014 ACR/ARHP Annual Meeting
Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission
Emanuela Bellis¹, Greta Carrara², Carlo Alberto Scirè², Alessandra Bortoluzzi³, Alberto Batticciotto⁴, Antonella Adinolfi⁵, Giovanni Cagnotto⁶, Marta Caprioli⁷, Marco Canzoni⁸, Francesco Cavatorta⁹, Fulvia Ceccarelli¹⁰, Orazio De Lucia¹¹, Valentina Di Sabatino¹², Antonella Draghessi¹³, Georgios Filippou¹², Ilaria Farina³, Maria Cristina Focherini¹⁴, Paola Frallonardo¹⁵, Alessandra Gabba¹⁶, Angelica Gattamelata¹⁰, Marwin Gutierrez¹³, Luca Idolazzi¹⁷, Filippo Luccioli¹⁸, Pierluigi Macchioni¹⁹, Marco Massarotti²⁰, Claudio Mastaglio²¹, Luana Menza²¹, Giulia Mirabelli¹⁸, Maurizio Muratore²², Simone Parisi²³, Valentina Picerno¹², Matteo Piga²⁴, Roberta Ramonda²⁵, Bernd Raffeiner²⁶, Daniela Rossi²⁷, Paola Rossini²⁸, Garifallia Sakellariou^29,30, Crescenzio Scioscia³¹, Carlo Venditti³², Annamaria Iagnocco¹⁰ and Marco Matucci-Cerinic³³, ¹Rheumatology, Ospedale Mauriziano, Turin, Italy, ²Italian Society for Rheumatology, Milan, Italy, ³A.O.U. S.Anna di Cona, Ferrara, Italy, ⁴L.Sacco University Hospital, Milan, Italy, ⁵Policlinico le Scotte, Siena, Italy, ⁶IRCCS Policlinico San Matteo, Pavia, Italy, ⁷Istituto di Cura Città di Pavia, Pavia, Italy, ⁸A.O. Sant'Andrea, Rome, Italy, ⁹A.O.U.P. Santa Chiara, Trento, Italy, ¹⁰Sapienza University of Rome, Rome, Italy, ¹¹Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ¹²University of Siena, Siena, Italy, ¹³Università Politecnica delle Marche, Jesi, Italy, ¹⁴Ospedale Infermi, Rimini, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ¹⁶A.O.U. di Cagliari, Cagliari, Italy, ¹⁷Ospedale Civile Maggiore, Verona, Italy, ¹⁸University of Perugia, Perugia, Italy, ¹⁹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²⁰Istituto Clinico Humanitas, Rozzano, Italy, ²¹Moriggia-Pelascini, Gravedona, Italy, ²²Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, ²³A.O. Città della Salute e della Scienza di Torino, Turin, Italy, ²⁴Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²⁵Rheumatology Unit, Department of Medicine, University of Padua, Padova, Italy, ²⁶Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²⁷University of Turin, Turin, Italy, ²⁸P.O. “Destra Secchia”, Pieve di Coriano, Italy, ²⁹Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ³⁰Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ³¹University of Bari, Bari, Italy, ³²A.O. Rummo, Benevento, Italy, ³³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose Clinical remission is now an achievable goal in patients with rheumatoid arthritis (RA). Much has been done in order to better understand and define…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Martin J. Bergman¹, Jeffrey Yourish², Jinglan Pei², Jenny Devenport², William Reiss² and Edward Keystone³, ¹Taylor Hospital, Ridley Park, PA, ²Genentech, South San Francisco, CA, ³University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
Abstract Number: 129 • 2014 ACR/ARHP Annual Meeting
Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice
Petra Hanova¹, Jakub Zavada¹, Jana Hurnakova¹, Martin Klein¹, Olga Sleglova¹, Marta Olejarova¹, Martin Komarc², Ladislav ŠEnolt¹ and Karel Pavelka³, ¹Institute of Rheumatology, Charles University, 1st Medical Faculty, Prague, Czech Republic, ²Institute of Biophysics and Informatics, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: To evaluate if the 7-joint ultrasound scoring system (US7) is able to find synovitis in patients in remission of RA. Methods: Patients with rheumatoid…
Abstract Number: 122 • 2014 ACR/ARHP Annual Meeting
The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission
Gurjit S. Kaeley¹, Midori Jane Nishio², Janak Goyal³, Daryl MacCarter⁴, Alvin Wells⁵, Anabela Cardoso⁶, Shufang Liu⁷, Jasmina Kalabic⁸ and Hartmut Kupper⁸, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Raritan Bay Medical Center, Perth Amboy, NJ, ⁴Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁵Rheumatology & Immunotherapy Center, Franklin, WI, ⁶AbbVie, Amadora, Portugal, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose Patients (pts) with rheumatoid arthritis (RA), who achieve clinical disease remission by treatment with disease- modifying agents may have residual joint inflammation and vascularization,…
Abstract Number: 121 • 2014 ACR/ARHP Annual Meeting
Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission
Nathalie Filippi¹, Cédric Lukas², Jacques Morel³, Bernard Combe⁴ and Gael Mouterde⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁵Immunologie Rhumatologie, Hopital Lapeyronie, Montpellier, France
Background/Purpose Ultrasound (US) is a sensitive tool for the evaluation of joint inflammation in patients with RA, and can detect synovitis even when clinical remission…
Abstract Number: 120 • 2014 ACR/ARHP Annual Meeting
Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication?
Myrthe van der Ven¹, T. Martijn Kuijper¹, A. H. Gerards², Ilja Tchetverikov³, A.E.a.M. Weel^1,4, D. van Zeben⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ³Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Tapering medication in rheumatoid arthritis (RA) patients is becoming increasingly important due to the effectiveness of both biological therapy and tight-controlled treatment. Patients are…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Abstract Number: 2974 • 2014 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score Is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State
Margaret H. Ma¹, Toby Garrood², Wanying Li³, Nadine A. Defranoux³, Gabrielle H. Kingsley⁴, Andrew P. Cope⁵ and David L. Scott⁶, ¹King's College Hospital, London, United Kingdom, ²Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Academic Rheumatology, Kings College London, London, United Kingdom, ⁵Academic Dept Rheumatology, King's College London, London, United Kingdom, ⁶King's College London, Department of Rheumatology, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) patients increasingly achieve clinical remission with intensive treatment regimens. However, ultrasound (US) subclinical synovitis has been reported in remission states. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.